Effect of aerosolized rhDNase (Pulmozyme®) on pulmonary colonization in patients with cystic fibrosis

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 9, 2006, Pages 1070-1074

  Frederiksen, Birgitte ^a   Pressler, Tacjana ^a   Hansen, Annelise ^a   Koch, Christian ^a   Høiby, Niels ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Bacterial colonization; Randomized; rhDNase

Indexed keywords

DORNASE ALFA;

AEROSOL; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM DETECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFECTION CONTROL; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NEBULIZER; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; INFANT; MALE; PNEUMONIA, BACTERIAL;

EID: 33748672304     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250600752466     Document Type: Article

References (28)

1. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
2. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139:813-20.
3. Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group. J Pediatr 1998;133: 486-91.
4. Høiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Paediat Scand Suppl 1982;301:33-54.
5. Høiby N, Frederiksen B. Microbiology of cystic fibrosis. In: Margaret ME, Hodson DE, Geddes M, Tranquilli WJ, Grimm KA, Lamont LA, et al, editors. Cystic fibrosis. Oxford: Oxford University Press; 2000. p. 83-107.
6. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5.
7. Polgar G, Promadhat V. Pulmonary function testing in children. Techniques and standards. Philadelphia: W. B. Saunders; 1971.
8. Chernick W. Comparison of tracheobronchial secretion in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959;24:739-45.
9. Matthews LW, Spector S, Lemm J, Potter JL. Studies on pulmonary secretions. I. The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1963; 88:199-204.
10. Chernick WS, Barbero GJ, Eichel HJ. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatric 1961;27:589-96.
11. Raskin P. Bronchospasm after inhalation of pancreatic doenase. Am Rev Respir Dis 1968;98:697-9.
12. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990;87:9188-92.
13. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 1992;267:1947-51.
14. Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342:199-202.
15. Hubbard R, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, et al. A preliminary study of aerosolised recombinant human deoxyribonuclease in treatment of cystic fibrosis. N Engl J Med 1992;326:812-5.
16. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148: 145-51.
17. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 1997;131:118-24.
18. Hodson ME, Shah PL. DNase trials in cystic fibrosis. Eur Respir J 1995;8:1786-91.
19. Petersen NT, Høiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand 1981;70:623-8.
20. Foundation CF, Patient Registry Annual Report, 2003.
21. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;28:159-66.
22. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001;32:356-66.
23. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-204.
24. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-52.
25. Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002;165:904-10.
26. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-7.
27. Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 2005;39:1-4.
28. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-25.